Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03674138 · ClinicalTrials.gov registry record · NA
Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 99
- Enrollment target
NCT03674138 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 99 participants.
The verdict
NCT03674138, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
Study Summary
This is a prospective, randomized clinical trial to investigate the clinical impact of a preemptive pharmacogenomics strategy to guide antidepressant therapy in cancer patients. Those enrolled onto the clinical trial will be randomized to either DNA-guided choice of therapy or clinical management alone. Scores on self-reported measures of depressive and anxiety symptoms along with quality of life will be compared between cohorts.
Interventions
- DIAGNOSTIC_TEST DNA-guided choice of therapy
- OTHER Clinical management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2024-10-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03674138
The ClinicalTrials.gov registry entry for NCT03674138 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DNA-guided choice of therapy is the first listed.
NCT03674138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03674138 about?
NCT03674138 is a clinical study titled "Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients". This is a prospective, randomized clinical trial to investigate the clinical impact of a preemptive pharmacogenomics strategy to guide antidepressant therapy in cancer patients. Those enrolled onto the clinical trial will be randomized to either DNA-guided choice of therapy or clinical management al...
What is the current status of trial NCT03674138?
This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2018-09-12. Estimated completion is 2024-10-27.
What interventions are being tested in trial NCT03674138?
The interventions under investigation include: DNA-guided choice of therapy (DIAGNOSTIC_TEST), Clinical management (OTHER).
Who is sponsoring clinical trial NCT03674138?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.